CJC-1295 and the engineering problem GHRH was never going to solve.

Native growth-hormone-releasing hormone is a 44-amino-acid peptide secreted by the arcuate nucleus of the hypothalamus into the hypophyseal portal system. It binds the GHRHR on somatotrophs in the anterior pituitary, and within minutes drives a pulse of growth hormone release. It is also one of the shortest-lived signaling peptides in human physiology. Its plasma half-life is roughly 7 minutes. For decades, this was the engineering problem in GH-axis therapeutics: how to keep a signal alive long enough to dose.

Tesamorelin, approved by the FDA in 2010 for HIV-associated lipodystrophy, solved part of it with a trans-3-hexenoic acid modification that resists DPP-IV cleavage. Half-life rose to about 30 minutes. Useful, but not transformative.

The albumin trick

The team at ConjuChem Biotechnologies in Montreal — described in a 2005 paper by Léon Castaigne and colleagues in the Journal of Medicinal Chemistry — took a different approach. They started with the active 1–29 fragment of human GHRH, applied four amino-acid substitutions to confer DPP-IV resistance, and added a maleimidopropionic acid linker at the C-terminus. The linker reacts in vivo with the free thiol on Cysteine-34 of human serum albumin. After subcutaneous injection, the peptide forms a covalent conjugate with circulating albumin.

The molecule was not made longer-acting. Its carrier was. The peptide became a passenger on a protein with a 21-day clearance time.

The published Teichman 2006 phase I trial in JCEM, conducted at McGill University, showed what the engineering bought: in healthy adult volunteers, single subcutaneous doses of CJC-1295 produced 2–10× elevations in mean plasma GH for six days or longer, and 1.5–3× elevations in IGF-1 for nine to eleven days. Estimated half-life was 5.8 to 8.1 days.

DAC, non-DAC, and a vocabulary problem

The research literature distinguishes two CJC-1295 variants and the consumer literature frequently does not. The DAC variant — Drug Affinity Complex — carries the maleimide linker and forms the albumin conjugate. Half-life: roughly a week. The non-DAC variant, sometimes called Modified GRF (1-29), has the same four DPP-IV-resistant substitutions but lacks the linker. Half-life: roughly 30 minutes. These are different molecules with different pharmacokinetics and different physiological consequences.

Why a long half-life changes the physiology

GH secretion in healthy adults is pulsatile. The pituitary releases GH in episodic bursts — most prominently during slow-wave sleep — and the trough periods between pulses appear to matter for receptor desensitization. The pulsatile structure is part of how the axis works, not noise around it. The published data don't quite support the worry that sustained CJC-1295 exposure flattens the pulses: GH retains its pulsatile character, with the pulse amplitude rather than the frequency or trough behavior driving the IGF-1 response.

The non-obvious findings

First: GHRH has direct sleep-architecture effects independent of GH release. Work going back to Krueger and colleagues at Washington State in the 1990s shows that GHRH itself is somnogenic, increasing slow-wave-sleep time when administered centrally. The effect persists in animals where GH release has been pharmacologically blocked. The implication is that any long-acting GHRH analog has two mechanisms of action, not one — and the sleep effect, often dismissed as anecdotal in human studies, may be the more consistent of the two.

Second: a 2007 paper by Alba and colleagues in the American Journal of Physiology demonstrated that once-daily CJC-1295 administration normalized longitudinal growth in GHRH-knockout mice. The model isolates the GHRH signal — the mice have no endogenous GHRH — and shows that exogenous CJC-1295 fully rescues growth. This is the cleanest pharmacological evidence available that the molecule is acting on the GHRHR.

Often studied alongside

The canonical research pairing is CJC-1295 with ipamorelin. The two compounds act on different receptors — GHRHR for CJC-1295, GHSR (the ghrelin receptor) for ipamorelin — and the published mechanistic literature describes their combination as additive on GH amplitude. The pituitary somatotroph responds to GHRH stimulation by increasing the magnitude of its native pulses; it responds to GHSR stimulation by increasing both pulse amplitude and frequency.

There are no published long-term outcome trials of CJC-1295 in healthy adults — the Teichman work was a phase I PK/PD study. Clinical development was discontinued in 2008. The compound has no current sponsor pursuing approval.